BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
11/7/2018 2:30:08 AM | Browse: 953 | Download: 1353
 |
Received |
|
2018-08-18 08:40 |
|
Peer-Review Started |
|
2018-08-19 03:21 |
|
To Make the First Decision |
|
2018-10-08 02:59 |
|
Return for Revision |
|
2018-10-09 02:11 |
|
Revised |
|
2018-10-11 20:15 |
|
Second Decision |
|
2018-10-19 09:23 |
 |
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Company Editor-in-Chief |
|
2018-10-21 06:38 |
|
Articles in Press |
|
2018-10-21 06:38 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2018-11-06 03:50 |
|
Publish the Manuscript Online |
|
2018-11-07 02:30 |
| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2018. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Medicine, General & Internal |
| Manuscript Type |
Editorial |
| Article Title |
Chronic hepatitis C, atherosclerosis and cardiovascular disease: What impact of direct-acting antiviral treatments?
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Luigi Elio Adinolfi, Luca Rinaldi and Riccardo Nevola |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Luigi Elio Adinolfi, MD, Full Professor, Department of Medical, Surgical, Neurological, Metabolic, and Geriatric Sciences, University of Campania “L. Vanvitelli”, Piazza Miraglia, Naples 80138, Italy. luigielio.adinolfi@unicampania.it |
| Key Words |
Direct-acting antiviral agents; Hepatitis C virus; Atherosclerosis; Insulin resistance; Cardiovascular disease |
| Core Tip |
Chronic hepatitis C (HCV) infection is associated with an increased risk of atherosclerosis, cardiovascular disease and cardiovascular mortality. HCV lives within carotid plaques, promotes pro-atherogenic conditions such as pro-inflammatory cytokines, oxidative stress, insulin resistance, diabetes, steatosis, cryoglobulinemia and endotoxinemia. Direct-acting antiviral agents (DAA) are highly effective and safe therapeutic regimens. There are a number of studies showing that HCV clearance by DAAs is associated with an improvement in atherosclerosis and a reduced risk of cardiovascular events. In addition, HCV clearance is associated with improvement of metabolic and immunological conditions that promote cardiovascular disease. Further studies will be needed to confirm these promising data. |
| Publish Date |
2018-11-07 02:30 |
| Citation |
Adinolfi LE, Rinaldi L, Nevola R. Chronic hepatitis C, atherosclerosis and cardiovascular disease: What impact of direct-acting antiviral treatments? World J Gastroenterol 2018; 24(41): 4617-4621 |
| URL |
http://www.wjgnet.com/1007-9327/full/v24/i41/4617.htm |
| DOI |
http://dx.doi.org/10.3748/wjg.v24.i41.4617 |
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
